Open in PodwiseOpen

Podcast cover

BioCentury · Business

BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Episodes

Ep. 251 - Eyes on the target: a Back to School Overview

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

Ep. 248 - Grand Rounds Preview: Eyes on the Target

Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School

Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds

Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On

Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers

Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs

Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns

Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure

Ep. 240 - Chevron Ruling's Impact; Plus: Tumor Targets, Lurie Winner

Ep. 239 - Rare Disease Spotlight: MPS & DMD

Ep. 238 - Biosecure Act: The Impact & What's Ahead

Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS

Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma

Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations

Ep.234 - Biotech M&A, Biosecure Expands & ASCO Update

Ep.233 - ASCO Preview, Rare Diseases & Biogen M&A

Ep.232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data

Page 8

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise